Vascular Access · Long-Term AVF Care

Understanding Your Fistula After Years on Dialysis

Why it gets bigger, why some parts are soft and some are hard, and what it all means — for patients and the dialysis team that cares for them.

PublishedNailathalaGipatikPepalwal: ReferencesMga SanggunianMga TinubdanReng Reperensya: 4 Read timeOras ng pagbasaOras sa pagbasaOras ning pamamasa:
Filipino male dialysis patient examining his AVF with a nurse — long-term AVF care, by W Rivero, MD
Understanding Your Fistula After Years on Dialysis

Welcome. If you have been on dialysis for several years, your fistula has changed. It is bigger, perhaps twistier, with hard and soft areas you can feel under the skin. This guide explains why — in plain language — and what to watch for so we can keep it working for many more years.

The Living Fistula: How an AVF Is Born and How It Matures

A fistula begins as a surgical decision. Your vascular surgeon connects an artery (which carries blood under high pressure) to a nearby vein (which normally carries blood under very low pressure). The moment the two are joined, the vein is exposed to forces it was never designed to handle — pressures up to fifty times what it has carried for your whole life.

The vein responds. It does not stay still. Within hours, the inner lining of the vein begins to sense the new flow. Within days, the wall starts to thicken. Within weeks, the lumen — the space inside through which blood travels — widens. This whole process is called outward remodeling, and it is the body's way of saying: "I will become strong enough to carry this load."

We call the early phase maturation. A useful rule that vascular surgeons follow is the rule of 6s: by six weeks after surgery, the vein in the cannulation segment should be at least 6 millimetres wide, no deeper than 6 millimetres from the skin, and carrying a flow of at least 600 millilitres per minute. When all three are reached, your fistula is mature enough to be needled safely for dialysis.

But maturation does not stop at six weeks. It continues for months and years. After five years of dialysis, your fistula often looks nothing like it did at creation. It is larger, sometimes much larger. Parts of it may bulge. Parts may feel firmer. The course of the fistula under your skin may have curved or coiled. This is not failure — it is the long-term result of carrying arterial-level blood through what was originally a thin-walled vein.

The driver of all this change is wall shear stress — the friction your blood creates as it slides along the inner wall. Think of a river: the faster the water flows, the more it shapes the banks. Your fistula is the river. Your vein wall is the bank. Year after year, the flow shapes the wall.

AVF maturation timeline from surgical creation through year 5, with cross-sectional wall appearance at each stage — diagram — by W Rivero, MD
© williamriveromd.com

Why AVFs Grow Gigantic: The Biology of Long-Term Venous Arterialization

Think about the math. Three sessions per week, four hours per session, for five years equals roughly 3,000 hours of arterial-pressure flow through a vein. The vein is constantly being asked to dilate, to remodel, to accommodate. Over years, this repeated signal pushes the wall toward larger and larger diameters. This is why your fistula is bigger today than it was at year one.

Some patients dilate more than others. The strongest risk factors for excessive enlargement are:

  • Uncontrolled hypertension — higher pressure means more force on the wall.
  • Proximal access — upper-arm fistulas tend to carry higher flows than forearm fistulas, so they dilate more aggressively.
  • Naturally high-flow AVFs — some fistulas carry 1.5 to 2 litres of blood per minute, and over years that volume forces continuous outward remodeling.
  • Large surgical anastomosis — a wider connection at creation allows more flow from day one.
  • Genetic and inflammatory factors we still do not fully understand.

It is important to distinguish physiologic enlargement — gradual, uniform widening of the whole fistula course, with intact skin — from pathologic aneurysmal change, which is more localized, faster-growing, and may threaten the skin overlying a particular bulge. Physiologic enlargement is normal and expected. Pathologic change requires attention.

Flow and pressure biology of AVF remodeling — normal vein, AVF, and mature enlarged AVF progression, diagram — by W Rivero, MD
© williamriveromd.com

The Hard Areas: What Creates Stiffness and Fibrosis

When you feel along your fistula, some areas are firm — almost like a small rope or ridge under the skin. These hard areas come from several layered processes that all share one theme: injury followed by scarring.

Each time a needle enters your fistula — three times a session, two needles per session, hundreds of sessions per year — there is a tiny injury to the wall. Inflammation arrives to heal it. Repair cells called myofibroblasts arrive, deposit collagen, and leave behind a small scar. Multiplied over years, these scars become palpable as a firm zone along the needling track.

Beyond needling, the inside of the vessel wall responds to flow with a process called intimal hyperplasia. Plain language: the cells that line the inside of your fistula multiply and thicken. Imagine a callus forming on the inside of the vessel. This callus narrows the lumen and stiffens the wall. It is especially common at the junction where the artery and vein were originally joined — the juxta-anastomotic region — and at curves and bends along the fistula course.

Other contributors to hard segments:

  • Mural thrombus — small clots that stick to the wall and organize into fibrotic cords over time.
  • Calcification — calcium deposits in the vessel wall, common in people with long-standing kidney disease because phosphate, calcium, and parathyroid hormone are difficult to balance.

There is a useful paradox to remember: hard areas are often the most narrowed but the least likely to rupture. The scarring itself acts as reinforcement. The areas that worry vascular specialists are usually soft bulging areas, not the firm ones. That said, when a hard zone forms close to the anastomosis at the elbow or wrist, it often signals an inflow stenosis — a narrowing that is making your fistula work harder upstream. This is treatable, and your dialysis team should know about it.

The Soft Areas: Aneurysms, Pseudoaneurysms, and Pulsatile Pouches

The bulging soft pouches you feel along your fistula are not all the same thing, and the distinction matters.

True aneurysm

A true aneurysm is a widening of the fistula that involves all three layers of the vessel wall — the inner lining, the muscle layer, and the outer covering. It develops slowly over years. It is usually uniform, follows the course of the fistula, and is strongly pulsatile and "thrilling" when you press over it. Because all three wall layers are present, true aneurysms have some intrinsic strength, even when large.

Pseudoaneurysm

A pseudoaneurysm is different. It happens when a needle puncture creates a small defect in the wall that does not fully heal. Blood escapes through the defect into the surrounding tissue and forms a contained collection, walled off only by scar tissue and skin. There is no true vessel wall around a pseudoaneurysm — and that is what makes them more dangerous than true aneurysms of similar size. They tend to be more localized (think of a small balloon attached to a larger pipe by a narrow neck), and they often form at buttonhole needling sites, where the same hole is used session after session.

How to tell the difference (clinically)

  • True aneurysm: smooth, gradual along the fistula course, pulsatile, has a thrill.
  • Pseudoaneurysm: localized "pouch," sometimes with a palpable neck, less uniform, more concerning when growing rapidly.

The Da Silva grading system (patient-friendly version)

Vascular surgeons use a four-level grading system originally described by Da Silva:

  • Type I — Diffuse dilation. The fistula is widened but there are no localized bulges. Skin is healthy. Monitor.
  • Type II — Localized aneurysm. A pouch is present but the skin over it is intact. Monitor closely; intervention may be needed if it grows.
  • Type III — Skin involved. The skin over the bulge is thinning, shiny, dark, or hair-bare. Threatened — needs urgent surgical review.
  • Type IV — Skin broken or infected. Scab, eschar, ulcer, or active infection present. Emergency — needs same-day care.

When soft is dangerous. A soft area becomes dangerous when any of these appear: skin thinning to a glassy, shiny appearance; loss of hair over the bulge; dark, purple, or black discoloration; rapid increase in size; spontaneous pain at the site; or any scab, blister, or open wound. Any of these should prompt an immediate call to your dialysis centre.

One final note: when the venous outflow above your fistula is narrowed (called central or outflow stenosis), pressure backs up downstream. That elevated pressure can make the fistula segment proximal to it balloon outward more quickly than it otherwise would. This is one reason your vascular team will sometimes order a venogram or fistulogram even when the bulging segment itself looks straightforward.

Hard fibrotic vs soft pseudoaneurysmal AVF segments — cross-section comparison — by W Rivero, MD
© williamriveromd.com
Da Silva Type I through IV aneurysm grading — clinical reference card — by W Rivero, MD
© williamriveromd.com

Tortuosity: Why the Fistula Coils and Twists

Older fistulas often follow a coiled or S-shaped path under the skin. There is a geometric reason for this. As the fistula lumen widens — and the wall thickens — the vein lengthens as well. The vein has no rigid bone-tendon attachments holding it straight, so the extra length has to go somewhere. It curls.

At every bend, the flow becomes turbulent — meaning the blood does not move smoothly. Turbulent flow causes local injury, which causes local remodeling, which deepens the bend. The process feeds itself. This is why upper-arm fistulas, which have more "free length" in the arm tissue, tend to become more tortuous over years than forearm fistulas, which are anchored against bone.

Tortuosity has real clinical consequences:

  • Cannulation becomes harder. Needling along curved segments is technically more difficult and infiltrations (leaks during needling) are more common.
  • Kinking versus angulation matters. A gentle curve usually causes no flow disturbance. A sharp kink, especially with arm position changes, can choke flow and even thrombose the fistula.
  • Surveillance is harder. A coiled fistula is more challenging to scan with ultrasound, and stenoses can hide inside the curves.

If a particular bend is causing repeated cannulation failures or you can feel flow changing with arm position, raise this with your dialysis team.

Surveillance: Reading Your Fistula

Your fistula tells you what is happening — if you know how to listen. The international standard set by the KDOQI Vascular Access Guidelines is a short physical exam by your dialysis nurse at every session and a more thorough exam at least monthly. You can do a simpler version at home every day.

Home self-monitoring: LOOK · FEEL · LISTEN

LOOK. Look at the skin over your fistula every day. Note anything new: redness, swelling, change in colour, new bulges, hair loss in a particular spot, shiny patches, blisters, scabs, or any sweat-like discharge. A small change one day may not matter; the same change persisting for several days is worth reporting.

FEEL. Place your fingers lightly along the entire length of the fistula. You should feel a continuous thrill — a soft, vibrating, buzzing sensation. The thrill should be present at the anastomosis, along the body of the fistula, and proximally. Any segment where the thrill becomes a sharp pulse instead of a continuous hum suggests a narrowing nearby. Loss of the thrill entirely is an emergency — your fistula may have clotted.

LISTEN. If you have a stethoscope (or use the bell of a doctor's stethoscope at the dialysis centre), the sound over a healthy fistula is a soft, continuous bruit — like a low whoosh that does not stop between heartbeats. A bruit that becomes high-pitched, pulsatile, or interrupted between heartbeats suggests a stenosis (narrowing) somewhere in the system.

Duplex ultrasound — when and why

A duplex ultrasound is a non-invasive scan that measures both the flow rate (Qa) inside your fistula and the anatomy of the wall and lumen. The KDOQI guidelines recommend duplex surveillance at least every 6 to 12 months in a mature, well-functioning fistula, and sooner if anything new arises — including a new hard area, a new bulge that is growing, persistent post-needling bleeding, a thrill that has changed, or a drop in dialysis efficiency (low Kt/V).

Cardiac consequence — why your nephrologist asks about shortness of breath

A very high-flow fistula (more than 1.5 to 2 litres per minute) recirculates a lot of blood from the artery directly to the vein, bypassing the body's tissues. The heart has to work harder to maintain perfusion. Over years, this can enlarge the left side of the heart and contribute to heart failure. If you ever have new breathlessness, unexplained swelling not relieved by dialysis, or fatigue out of proportion to your sessions — tell your nephrologist. We can check this with an echo and a flow measurement.

LOOK-FEEL-LISTEN home monitoring method for daily AVF assessment — patient education poster — by W Rivero, MD
© williamriveromd.com

When Should Surgery Be Considered?

Most enlarged, tortuous fistulas do not need surgery. The first line of management is always conservative: careful monitoring, skin care, controlled blood pressure, and a smart needling strategy. If something does need to be done, there are options short of full surgery, and surgical options short of losing your access.

Conservative care. Watchful surveillance, skin protection, rotation of needle sites, optimization of dialysis prescription, and control of blood pressure and anaemia. The majority of patients with large, mature, tortuous AVFs are managed this way for years.

Interventional radiology (angioplasty / PTA). If a narrowing upstream is making the fistula work harder and is driving downstream dilation, a balloon angioplasty (sometimes with a stent) can re-open the narrowed segment. This is the most common access intervention performed worldwide. It is done through a small needle puncture, often as a day procedure, and your fistula can usually be used within 24 hours.

Surgical options — in plain language:

  • Aneurysmorrhaphy (wall plication). The surgeon opens the bulging segment, trims away the excess wall, and reconstructs the lumen at a more normal size. The fistula is preserved.
  • Segmental resection with reconstruction. The diseased segment is cut out and the two healthy ends are rejoined, sometimes with a short bridging piece of vein or graft material.
  • Banding. For a fistula carrying too much flow and stressing the heart, a tight band is placed surgically around a short segment to reduce the flow to a safer level.
  • Ligation and conversion to an AVG. When a fistula cannot be salvaged, it is tied off and a synthetic graft (AVG) is created elsewhere to continue dialysis.

The decision principle. Function preserved or function threatened — these are the questions vascular surgeons ask. Pure cosmesis is rarely an indication for surgery on its own, because every intervention carries some risk of losing the access altogether.

In the Philippine setting. Vascular surgical referral is arranged through your nephrologist and your dialysis centre. Major access centres include the National Kidney and Transplant Institute (NKTI), the Philippine General Hospital (PGH), the University of Santo Tomas Hospital, St. Luke's Medical Center, Makati Medical Center, and Asian Hospital, among others. Ask your team which centre is most accessible for you.

High-Output Heart Failure from a Giant AVF

This is the most underrecognized complication of long-term, high-flow fistulas — and one that we as nephrologists actively look for.

Think of your fistula as a short circuit. Blood that would normally have to travel through your body's tissues — meeting resistance the whole way — instead takes a shortcut from artery directly to vein. When the shortcut is small, the heart barely notices. When the shortcut is carrying one and a half to two litres of blood every minute, the heart must work much harder to keep enough blood flowing to the rest of the body. Over years, this extra work enlarges the left ventricle and can eventually weaken it.

Symptoms. The clues are easy to dismiss because they overlap with everyday dialysis experiences:

  • New or worsening shortness of breath, especially on exertion or lying flat at night.
  • Swelling of the legs or face that is not relieved by your usual dialysis session.
  • Fatigue out of proportion to what your sessions normally cause.

The Nicoladoni–Branham sign — at the bedside. Your doctor may temporarily compress the body of your fistula with a finger while monitoring your pulse. If your heart rate drops noticeably when the fistula is occluded — usually by five to ten beats per minute or more — it is a strong sign that the fistula is contributing significantly to your cardiac workload. It is named for the two physicians who first described this finding more than a century ago.

Assessment. A combination of duplex ultrasound (to measure Qa, your access flow) and an echocardiogram (to measure your heart's size and function) gives us the answers we need.

Management. When intervention is needed, banding — surgically narrowing the fistula to reduce its flow — is usually preferred over ligation, because it preserves the access. Banding aims to bring the flow back into a safer range (typically around 700 to 1000 mL/min) and is often followed over months by partial reversal of the cardiac enlargement.

Cosmetic Concerns: Honest Counseling

Let us speak honestly. A large, coiled, visibly bulging fistula on your forearm or upper arm is a striking change. People notice. You notice. You may dress around it, hide it under long sleeves, or feel self-conscious in social situations. Your distress about this is real and legitimate — it is not vanity.

It is also true that we cannot make the fistula disappear without risking the access itself. Aggressive intervention purely for cosmesis carries a real chance of losing the fistula altogether, and your fistula is what keeps you alive between sessions. So when a vascular surgeon declines to "fix" the appearance of a functioning fistula, it is not dismissal — it is risk-balanced judgment.

What can be done:

  • When intervention is medically indicated (skin compromise, high cardiac flow, recurrent bleeding, or significant pseudoaneurysm), the surgical repair often improves appearance as a secondary benefit.
  • Skin care over aneurysmal segments — gentle cleansing, daily moisturizer, sun protection — can keep the skin healthier and reduce visible pigmentation changes.
  • Clothing adaptations: long sleeves, sleeve garments, looser cuffs, light wraps. These should not be tight enough to compress the fistula.
  • Arm positioning in photographs and social settings — a learned skill that many long-term patients develop on their own.

If cosmetic distress is affecting your mood, your relationships, or your willingness to dialyze, please tell us. Body-image distress is a documented and significant burden of long-term dialysis. It deserves to be named and addressed — sometimes by a counsellor, sometimes through peer support, and sometimes by being heard clearly by your medical team. None of this dismisses the underlying truth: your fistula is a lifeline. Acknowledging cosmetic distress is not the opposite of gratitude for the access — it is part of treating the whole person.

Eight warning signs for dialysis access requiring immediate emergency care — patient education poster — by W Rivero, MD
© williamriveromd.com

Go to Your Dialysis Center or Emergency Room Immediately If You Notice:

  1. Skin over the fistula is turning very thin, shiny, or dark.
  2. A blister, sore, scab, or open wound over a bulge.
  3. Sudden rapid increase in the size of a soft area.
  4. Spontaneous bleeding from the fistula site.
  5. No thrill (buzzing sensation) when you touch the fistula.
  6. Arm is cold, numb, or painful below the fistula.
  7. Signs of infection: redness, warmth, pus, fever.
  8. Unusual shortness of breath or swelling not explained by missed dialysis.

Protecting Your Fistula for the Long Term

The rules are short, the discipline is lifelong.

  • No blood pressure cuffs, no blood draws, no IV lines on your fistula arm — ever. Tell every healthcare worker who approaches your arm. Wear an alert band if helpful.
  • Skin care over aneurysmal segments. Daily gentle wash, daily moisturizer, daily inspection. Avoid harsh soaps and abrasive scrubbing. Protect from sun.
  • Rope-ladder needling. Ask your dialysis nurses to rotate your needling sites along the entire usable length of the fistula. The same hole used session after session (buttonhole) injures one spot repeatedly and can drive pseudoaneurysm formation.
  • If pseudoaneurysms are forming, stop the buttonhole technique. Have this conversation with your dialysis team.
  • Sleep positioning. Try not to lie on your fistula arm for prolonged periods. Some patients put a small pillow as a reminder.
  • Avoid tight watches, bracelets, and tight sleeves on the fistula arm.
  • Carry a card in your wallet noting: "Dialysis access on [left/right] arm — do not stick, do not measure BP."
  • Report any change in thrill, bruit, or appearance to your dialysis team — same day if possible.
  • Keep your blood pressure controlled. Uncontrolled hypertension accelerates aneurysmal degeneration.
  • Keep your phosphate, calcium, and PTH at target. Mineral imbalances drive vascular calcification, which damages your access.
Ten rules for protecting your fistula for the long term — patient education poster — by W Rivero, MD
© williamriveromd.com

Questions to Ask Your Dialysis Team and Surgeon

Bring this list with you. You are entitled to clear answers.

About needling and site rotation

  • What needling technique is being used on my fistula — rope ladder, buttonhole, or area puncture?
  • Are my needle sites being rotated along the full length of my fistula?
  • If buttonhole is being used and I have new bulges, can we switch to rope ladder?

About surveillance

  • When was my last duplex ultrasound? When is the next one scheduled?
  • Has my access flow (Qa) been measured? What was the number?
  • Is there any sign of stenosis on the monthly physical examination?

About surgery and referral

  • If a soft area continues to grow, at what point will I be referred to a vascular surgeon?
  • What is the threshold for skin compromise that would mean urgent surgery?
  • What are my options if the fistula cannot be saved — graft, peritoneal dialysis, or transplant evaluation?

About the heart

  • Given how mature my fistula is, should I have an echocardiogram?
  • Has anyone calculated my Qa to cardiac output ratio?

About home monitoring

  • What specifically should I watch for at home, between dialysis sessions?
  • Who do I call if I notice any of the warning signs after hours?
⚕ Clinician Reference
Nephrology · Vascular Access · Philippines Context

Understanding the Long-Term AVF
Hemodynamics, histopathology, surveillance, surgery, cardiac sequelae

A clinical reference on long-term AVF remodeling — aneurysmal degeneration, intimal hyperplasia, tortuosity, surveillance, and high-output cardiac sequelae. Aligned with KDOQI 2019 Vascular Access Guidelines, EVAS 2019, and KDIGO 2017 CKD-MBD. Philippine practice context throughout.

Author: W Rivero, MD, FPCP, DPSN Specialty: Internal Medicine · Nephrology · Clinical Nutrition Last Reviewed:

Hemodynamic Remodeling: The Vascular Biology of Arteriovenous Access

Arteriovenous anastomosis abruptly subjects the venous endothelium to arterial pressure and supraphysiologic wall shear stress (WSS). The endothelial response is biphasic and spatially heterogeneous, determining the long-term phenotype of the access.

WSS signaling axis

Laminar high WSS activates the endothelial mechanosensor complex (PECAM-1, VEGFR2, VE-cadherin), upregulating KLF2 and KLF4 transcription factors. KLF2/4 drive eNOS expression and nitric oxide (NO) synthesis, suppress NF-κB, and maintain a quiescent, contractile vascular smooth muscle cell (VSMC) phenotype. The result is favorable outward remodeling without intimal proliferation.

Conversely, low or oscillatory WSS — characteristically at the anastomotic heel, on the outer curvature of bends, and downstream of stenotic lesions — suppresses KLF2 expression, activates NF-κB, and recruits leukocytes. VSMCs undergo phenotypic switching to a synthetic state (reduced SM-MHC, calponin, SM22α; increased MMP-9, osteopontin), migrate intimally, and proliferate. This is the cellular substrate of intimal hyperplasia.

Outward remodeling and aneurysmal dilation

Sustained high WSS at the dilating outer wall provokes MMP-2 and MMP-9 mediated degradation of elastin and disruption of the internal elastic lamina. Without elastin, the wall loses recoil; circumferential stress per Laplace's law (T = P·r/h) rises as the radius increases, perpetuating outward remodeling toward aneurysmal dimensions.

Mechanotransduction pathways

Integrin engagement at the abluminal surface initiates focal adhesion kinase (FAK) signaling, with downstream PI3K/Akt and Rho-GTPase activation driving cytoskeletal remodeling and altered gene expression. TGF-β1, released from injured endothelium and infiltrating leukocytes, drives adventitial fibroblast-to-myofibroblast transition, ECM deposition, and the dense periadventitial fibrosis characteristic of mature accesses.

Cumulative flow-injury

Each cannulation produces focal endothelial denudation and medial trauma. At three sessions weekly, two needles per session, the access sustains over 300 cannulations annually. Layered with continuous arterial-pressure exposure (~3,000 hours over five years), the cumulative injury manifests as the heterogeneous landscape of fibrotic and aneurysmal segments coexisting along the same access.

Histopathology of the Mature AVF Wall

Intimal hyperplasia

Neointimal lesions are composed predominantly of phenotypically modulated (synthetic) VSMCs and myofibroblasts in a collagen-rich, proteoglycan-rich ECM. Lesional VSMCs downregulate contractile markers (SM-MHC, calponin, SM22α) and upregulate MMPs and osteopontin. Lesion expansion is driven by PDGF-BB and FGF-2 paracrine signaling from activated endothelium and infiltrating macrophages. The internal elastic lamina shows fragmentation in long-standing lesions.

Medial changes

Early adaptive medial SMC hypertrophy in response to elevated circumferential stress is followed in chronic accesses by SMC dropout, apoptotic loss, and progressive fibrotic replacement. Vasa vasorum changes may contribute to medial ischemia in larger calibres.

Adventitial remodeling

Neovascularization, fibroblast and myofibroblast proliferation, and dense collagen deposition transform the adventitia into the principal load-bearing layer of advanced aneurysmal segments. The adventitial mantle may be the only intact structural element preventing rupture in some Da Silva Type II–III aneurysms.

Pseudoaneurysm microanatomy

Pseudoaneurysms lack the three-layered architecture of true vessels. A wall defect — typically a non-healing cannulation injury — permits extravasation. The contained hematoma organizes, and a fibrous capsule forms from fibrin organization, granulation tissue, and chronic inflammatory infiltrate. The "wall" is reactive tissue, not endothelialized vessel. This distinguishes pseudoaneurysms from true aneurysms histologically and explains their disproportionate rupture risk.

True aneurysms

All three wall layers are present but attenuated. Elastin fragmentation removes vasoconstrictive recoil; medial thinning reduces tensile capacity; intimal disorganization may include focal hyperplasia coexisting with atrophy. Laplace's law explains the progressive nature of dilation once initiated.

Vascular calcification

Mönckeberg-type medial calcification predominates in ESKD-associated calcified access segments. Pathogenesis: hyperphosphatemia drives VSMC osteoblastic transdifferentiation via Pit-1 sodium-phosphate cotransporter activation, with upregulation of Runx2/Cbfa1, BMP-2, alkaline phosphatase, and osteocalcin. Apoptotic VSMC bodies serve as nidi for matrix calcification. Concurrent reduction in calcification inhibitors — fetuin-A, matrix Gla protein (MGP), pyrophosphate, OPG/RANKL imbalance — removes the brake on mineral deposition.

Needle track and buttonhole histology

Repeatedly cannulated segments show focal dense scar with disrupted wall architecture. Established buttonhole tracts demonstrate an epithelialized channel with surrounding granulation tissue; loss of tract integrity is the histologic substrate for pseudoaneurysm formation and infection.

AVF wall histopathology at three timepoints — normal vein, early AVF with intimal hyperplasia, late AVF with pseudoaneurysm/fibrotic/calcified zones; clinician reference — by W Rivero, MD
© williamriveromd.com

Classification Systems for AVF Aneurysms

Da Silva grading

TypeFindingsSkinAction
IDiffuse non-localized dilation; no true aneurysmal sacIntact, normalSurveillance; address modifiable drivers (HTN, high Qa)
IILocalized true aneurysm; size variableIntact, normalSurveillance with closer interval; intervention if growth >50%/yr or cardiac compromise
IIIAneurysm with skin compromise — thinning, shiny, hair loss, hyperpigmentationThreatenedUrgent vascular surgery referral; avoid cannulation over compromised skin
IVSkin breakdown — eschar, ulcer, blistering — or active infectionDisruptedEmergent surgical management; admit; broad-spectrum antibiotics if infected

NKF/KDOQI surveillance criteria (2019)

Monthly physical exam by trained staff (inspection, palpation, auscultation, augmentation test, pulse augmentation test); duplex when physical exam abnormality, Qa drop >25% from baseline, recirculation, persistent post-cannulation bleeding, or unexplained increase in venous pressures during HD.

EVAS 2019 size and growth thresholds

  • Aneurysm definition: >3× adjacent native vein diameter or absolute diameter >2 cm
  • Intervention indication: skin compromise, infection, growth >50% per year, absolute diameter ≥4 cm, cardiac compromise, or symptomatic mass effect

Aneurysm vs. pseudoaneurysm — duplex differentiation

FeatureTrue aneurysmPseudoaneurysm
WallAll three layers present (attenuated)Reactive capsule only — no true wall
Connection to parent vesselContinuous lumen, diffuseNarrow neck, focal
Color DopplerUniform forward flow with mild swirlingYin-yang sign — forward + reverse flow within sac
Spectral Doppler at neckSmooth waveformTo-and-fro pattern at neck
Internal flowLaminar to mildly turbulentSwirling, with central jet
Rupture risk per cm³LowerHigher

Duplex Ultrasound Surveillance: Parameters and Interpretation

Access flow (Qa)

Measured directly by duplex (PSV × cross-sectional area at the brachial artery typically) or intradialytic ultrasound dilution (Transonic). Normal mature AVF: 600–1500 mL/min. High-output risk: >1500–2000 mL/min (correlate with cardiac assessment). Hypofunction: <600 mL/min — KDOQI threshold for further workup.

Resistive and pulsatility indices

RI = (PSV − EDV)/PSV. Mature, well-functioning AVF: typically 0.5–0.7. Elevated RI suggests downstream stenosis or distal obstructive lesion. PI provides complementary information on resistance.

Stenosis criteria

Peak systolic velocity ratio across a stenotic lesion: >2:1 hemodynamically significant; >3:1 severe. Combine with absolute PSV (significant stenosis usually shows PSV >400 cm/s). The juxta-anastomotic segment is the most common site of inflow stenosis; the cephalic arch and basilic vein deep transposition are common outflow sites.

Pseudoaneurysm characterization

Document sac dimensions, neck width (narrow necks <0.5 cm carry higher rupture risk), wall thickness, swirling internal flow, and the yin-yang color Doppler sign. Serial measurements detect growth.

Wall thickness

Increased thickness with intimal hyperplasia; thinning in true aneurysmal segments. Measurement is technique-dependent; serial comparison by the same operator is more reliable than absolute values.

Qa/cardiac output ratio

Combined with transthoracic echocardiography. Qa/CO >20–30% predicts cardiac strain; >30–40% approaches indication for flow-reduction intervention.

Surveillance intervals

KDOQI 2019: every 6 months in stable mature AVF; sooner if clinical change or Qa drop. EVAS 2019: at least annually with size and flow documentation. In Philippine practice, duplex availability varies regionally — prioritize symptomatic patients and those with prior intervention.

Duplex surveillance parameters reference card — KDOQI and EVAS 2019 — by W Rivero, MD
© williamriveromd.com

High-Output Cardiac State: Recognition and Quantification

Definition

Cardiac output >8 L/min or cardiac index >4.0 L/min/m² attributable to AVF shunting, in the absence of competing high-output etiologies (severe anemia, thyrotoxicosis, wet beriberi, hepatic AV shunting, pregnancy).

Cardiac remodeling timeline

Compensatory eccentric LVH develops in response to chronic volume overload, with preserved or supranormal early EF, increased SV, and elevated CO. Progressive maladaptive remodeling — dilated LV cavity, eccentric hypertrophy beyond compensation, and eventual systolic dysfunction with reduced EF — may emerge over years if uncorrected. RV strain and secondary pulmonary hypertension can supervene.

Fistula flow as percent of cardiac output

Qa/CO >30% strongly correlates with cardiac strain; >40% is widely cited as an indication for flow-reduction intervention in symptomatic patients. The threshold for asymptomatic intervention remains debated and individualized.

Nicoladoni–Branham sign

Manual occlusion of the AVF body with sustained pressure for 30–60 seconds while monitoring heart rate. A decrease of ≥10 bpm or ≥5% from baseline supports significant cardiac contribution. Sensitivity is moderate; combine with echocardiographic Qa correlation for diagnostic certainty.

Echocardiographic findings

  • Dilated LV chamber (LVEDD, LVESD increased relative to body surface area)
  • Eccentric LVH (LV mass index elevated, relative wall thickness ≤0.42)
  • Initially preserved or supranormal LVEF, with hyperdynamic septum
  • Late: declining LVEF, reduced GLS on speckle-tracking
  • Possible RV dilation, elevated TR velocity if pulmonary HTN develops
  • Qa correlation: ideally measured at same encounter

Differential diagnosis of high-output failure in HD

Severe anemia (Hgb <7 g/dL); thyrotoxicosis; wet beriberi (thiamine deficiency, with notable prevalence in Philippine HD populations on inadequate nutrition); hepatic AV shunting (cirrhosis); pregnancy; obesity hypoventilation overlap. Always rule out competing etiologies before attributing high CO to the access alone.

Banding hemodynamics

Target post-banding Qa typically 700–1000 mL/min. Intraoperative flow measurement (Transonic or duplex) guides band tightening. Cardiac reverse remodeling — reduction in LV mass, normalization of CO — occurs partially over 6–12 months when banding is hemodynamically successful. Failed banding (residual Qa >1500 mL/min or recurrent symptoms) warrants reintervention or, ultimately, ligation with conversion to alternative access.

High-output cardiac failure pathway from AVF flow — pathophysiology mechanism — by W Rivero, MD
© williamriveromd.com

Surgical Decision Framework

Indication matrix

ScenarioPreferred approachUrgency
Da Silva I, intact skin, Qa <1500, no cardiac compromiseConservative surveillanceRoutine
Da Silva II, growth >50%/yr or Qa >1500 with symptomsElective aneurysmorrhaphy or bandingElective
Da Silva III — skin compromiseUrgent aneurysmorrhaphy or segmental resection≤2 weeks
Da Silva IV — skin breakdown or infectionEmergent surgical management; salvage vs. ligationSame day
High-output cardiac state (Qa/CO >30%, eccentric LVH, symptomatic)Banding (MILLER procedure or surgical narrowing)Elective–urgent
Steal syndrome with hand ischemiaDRIL or revision using distal inflowUrgent
Recurrent severe inflow stenosis after multiple PTASurgical revision with proximal anastomosisElective
Non-salvageable fistula with adequate alternative targetLigation + AVG (or new AVF if vessels permit)Elective

Operative options — principles

  • Aneurysmorrhaphy / plication. Longitudinal venotomy over the aneurysmal sac, excision of redundant wall, primary closure over a sizing catheter or mandrel to a target lumen (typically 6–8 mm). Patency reports range 70–85% at 12 months. Recurrence risk persists when underlying drivers (HTN, high Qa) are not addressed.
  • Segmental resection with interposition. Excision of the diseased segment with end-to-end reconstruction using autogenous vein where available, or PTFE/ePTFE interposition graft. Primary patency 60–75% at 1 year; secondary patency 80–90% with assisted maintenance.
  • Banding (MILLER procedure, brachial revision with surgical band, or external constriction). Reduces Qa to target. Intraoperative flow measurement is essential to avoid overcorrection and consequent thrombosis.
  • DRIL. Distal Revascularization with Interval Ligation for ischemic steal syndrome — reroutes distal flow via bypass graft from proximal artery to distal artery, with interval ligation just distal to the anastomosis.
  • Conversion to AVG. Loop forearm or upper-arm straight ePTFE configurations. Higher infection and thrombosis risk vs. AVF; useful when autogenous targets are exhausted.

Philippine context

Vascular access surgical referral is typically routed through the patient's nephrologist or dialysis-centre medical director. Major access centres include NKTI, PGH, USTH, St. Luke's Medical Center (Quezon City and BGC), Makati Medical Center, Cardinal Santos Medical Center, Asian Hospital and Medical Center, and several leading regional medical centres. HD bridging during operative repair is via tunneled central venous catheter or femoral catheterization; pre-operative discussion of bridging strategy is essential. The Philippine Society of Nephrology (PSN) Vascular Access Workshops provide standardized cannulation and surveillance training for dialysis staff.

Surgical decision algorithm for AVF aneurysmal change — clinical flowchart — by W Rivero, MD
© williamriveromd.com

Mineral Metabolism and Vascular Calcification in ESKD Access

CKD-MBD contribution to access calcification

Hyperphosphatemia is the central upstream driver. Intracellular phosphate entry via Pit-1 cotransporter activates Runx2/Cbfa1 transcription, BMP-2 expression, and alkaline phosphatase, driving osteoblastic transdifferentiation of vascular SMCs. Apoptotic VSMC bodies serve as nidi for matrix calcification.

FGF-23 / Klotho axis

FGF-23 rises early in CKD to maintain phosphate balance but contributes independently to LVH and cardiovascular mortality. Klotho deficiency removes a critical brake on vascular calcification and accelerates the vascular aging phenotype seen in ESKD.

Calciphylaxis

Calcific uremic arteriolopathy with thrombotic occlusion and ischemic necrosis. Risk factors: warfarin use, severe hyperphosphatemia, secondary hyperparathyroidism, female sex, diabetes, obesity, and protein C/S deficiency. Calcified AVF segments can be involved or coexist; presence in any ESKD patient should prompt review of mineral metabolism targets and warfarin necessity.

Targets (KDIGO 2017 CKD-MBD)

  • Phosphate: avoid sustained hyperphosphatemia; toward normal range in dialysis
  • Calcium: avoid hypercalcemia
  • iPTH: 2–9× upper limit of normal in dialysis patients; trends matter more than single values
  • Individualize targets; avoid suppression of PTH below baseline

Therapeutic implications for access longevity

  • Non-calcium phosphate binders (sevelamer, lanthanum carbonate, sucroferric oxyhydroxide) preferred in patients with documented vascular calcification
  • Calcimimetics (cinacalcet, etelcalcetide) — EVOLVE and IMPACT-SHPT data support PTH reduction and slowed progression of vascular calcification
  • Active vitamin D analogs — balance benefit against hypercalcemia risk
  • Dialysate calcium individualization
  • Avoid warfarin where alternatives exist in patients with calciphylaxis risk; consider apixaban with renal dose adjustment per current evidence

Infection and Pseudoaneurysm: A Dangerous Intersection

Microbiology

Staphylococcus aureus predominates (>70% of access infections), with MRSA prevalence elevated in dialysis populations. Streptococcus species, Pseudomonas aeruginosa, and Enterococcus species are recognized but less common. Polymicrobial infection is uncommon outside of skin breakdown and chronic ulceration.

Risk factors

  • Buttonhole cannulation technique — multiple studies show 3–5× higher infection rate vs. rope ladder
  • Diabetes mellitus
  • Immunosuppression
  • Skin breakdown over aneurysmal segment
  • Prior bacteremia, recurrent access infection
  • Poor hand hygiene at cannulation site, suboptimal aseptic technique

Presentation vs. sterile expanding hematoma

Infected pseudoaneurysm classically presents with pain disproportionate to size, erythema and warmth extending beyond the sac, purulent drainage, low-grade or high-grade fever, and systemic inflammatory markers (leukocytosis, elevated CRP, elevated procalcitonin in bacteremic patients). Sterile expansion is typically painless and indolent.

Management

  • Blood cultures × 2 before antibiotic initiation when feasible
  • Surface swab and aspirate cultures of any expressible drainage
  • Empiric IV vancomycin + cefepime or piperacillin-tazobactam pending sensitivities; adjust per institutional antibiogram
  • Urgent vascular surgical evaluation: salvage attempt (resection of involved segment with autogenous interposition where feasible) vs. ligation when irrecoverable
  • Immediate cessation of cannulation in the involved segment; consider tunneled CVC for ongoing HD
  • Anticoagulation only if clear thrombosis indication separate from infection
  • Echocardiography to assess for endocarditis if bacteremia or persistent fever

Absolute contraindication

Never cannulate through compromised, infected, or eschar-covered skin over an aneurysm. Skip the segment; if no alternative cannulation site exists, transition to CVC bridge while surgical planning proceeds.

Cannulation Strategy for the Mature, Aneurysmal, Tortuous AVF

Technique comparison

TechniqueDescriptionAneurysm riskInfection riskUse in mature aneurysmal AVF
Rope ladderRotating sites along the full usable lengthLowestLowestPreferred
ButtonholeSame exact site each session via an epithelialized tractHigh (pseudoaneurysm)High (incl. S. aureus bacteremia)Avoid when pseudoaneurysms forming
Area punctureClustered punctures in a narrow zoneHighest — accelerates aneurysmal degenerationModerate–highAvoid in all cases

Buttonhole abandonment criteria

  • Pseudoaneurysm formation at or near the buttonhole site
  • Recurrent infection, even mild, at the buttonhole tract
  • Scarring preventing dilator entry without force
  • Skin breakdown over the tract
  • Documented S. aureus bacteremia traceable to the access

Ultrasound-guided cannulation

Indications: tortuous fistula course, deep AVF (high-BMI patients, brachiocephalic transposition), repeated failed cannulation attempts (>2 attempts per session), prior infiltration, post-intervention. Requires nursing training (NKF and PSN modules available). Reduces infiltration rates and improves first-stick success in challenging anatomies.

Needle selection

14–17G typical; smaller gauge appropriate for thin-walled aneurysmal segments. Bevel-up orientation for the venous (downstream) needle to minimize back-wall puncture in tortuous segments. Sharper needles for first sticks; blunt needles only on established buttonhole tracts.

Rotation mapping and documentation

Nursing teams should maintain a documented site rotation chart for each patient. Photographic mapping is valuable for buttonhole sites where used. Each cannulation should be recorded with site, needle gauge, attempts, and any complications, accessible to all dialysis staff caring for the patient.

Infiltration management

Immediate withdrawal, manual pressure proximal to the infiltration, elevation, intermittent ice for the first 24 hours. Document extent. Reassess at the next session; consider duplex if extensive or if hematoma is expanding. Most infiltrations resolve without sequelae; large infiltrations may require temporary alternative cannulation site or short-term CVC bridge.

Evidence Summary and Guidelines Crosswalk

Major guideline documents

  • NKF KDOQI Clinical Practice Guideline for Vascular Access: 2019 Update (AJKD 2020;75[4 Suppl 2]:S1–S164). Monthly physical exam minimum; duplex when physical exam abnormality or Qa change; surgical referral for skin compromise, infection, or rapid growth.
  • EVAS / European Society for Vascular Surgery 2019 Clinical Practice Guidelines on the Management of Vascular Access for Haemodialysis. Aneurysm definition >3× adjacent native vein diameter; intervention thresholds for skin compromise, infection, growth >50%/yr, ≥4 cm absolute size, or cardiac compromise.
  • ERA-EDTA position statements — broadly aligned with KDOQI; emphasize proactive surveillance over reactive management.
  • KDIGO 2017 CKD-MBD Update — relevant for vascular calcification context in access longevity.

Observational evidence base

  • Aneurysmorrhaphy 12-month patency 70–85% (multiple single-centre series, including Henke et al., Ann Vasc Surg)
  • Banding for high-flow AVF — partial cardiac reverse remodeling (LV mass reduction, CO normalization) in approximately 70% at 6 months (MILLER procedure data and subsequent series)
  • Pseudoaneurysm rupture: mortality reports up to 20% when presentation is delayed; emphasizes the importance of pre-emptive surgical referral
  • Buttonhole vs. rope ladder: Muir et al. (AJKD 2014) and subsequent meta-analyses demonstrate higher S. aureus infection rates with buttonhole; favor rope ladder for new AVFs

Evidence gaps

  • No randomized controlled trial directly comparing aneurysmorrhaphy vs. segmental resection with interposition
  • Limited prospective data on optimal Qa threshold for asymptomatic flow reduction
  • Sparse data on outcomes of stent-graft repair of pseudoaneurysm in AVF (most data extrapolated from AVG literature)
  • Heterogeneous reporting of cardiac remodeling outcomes post-banding

Philippine practice context

  • Philippine Society of Nephrology (PSN) publishes vascular access care standards; PSN Vascular Access Workshops provide standardized cannulation training
  • Duplex availability is concentrated in tertiary centres; provincial dialysis units may rely more heavily on physical examination surveillance
  • Access coordinator roles are growing in major centres; encourage standardized handover between dialysis unit and surgical team
  • PhilHealth Z-Benefit packages cover certain access-related surgical procedures; coordinate with hospital billing for current coverage
ReferencesMga SanggunianMga TinubdanReng Reperensya 4 sources
  1. Lok, C. E., Huber, T. S., Lee, T., Shenoy, S., Yevzlin, A. S., Abreo, K., Allon, M., Asif, A., Astor, B. C., Glickman, M. H., Graham, J., Moist, L. M., Rajan, D. K., Roberts, C., Vachharajani, T. J., & Valentini, R. P. (2020). KDOQI clinical practice guideline for vascular access: 2019 update. American Journal of Kidney Diseases, 75(4 Suppl 2), S1-S164. https://doi.org/10.1053/j.ajkd.2019.12.001
  2. Schmidli, J., Widmer, M. K., Basile, C., de Donato, G., Gallieni, M., Gibbons, C. P., Haage, P., Hamilton, G., Hedin, U., Kamper, L., Lazarides, M. K., Lindsey, B., Mestres, G., Pegoraro, M., Roy, J., Setacci, C., Shemesh, D., Tordoir, J. H. M., & van Loon, M. (2018). Editor's choice — Vascular access: 2018 clinical practice guidelines of the European Society for Vascular Surgery (ESVS). European Journal of Vascular and Endovascular Surgery, 55(6), 757-818. https://doi.org/10.1016/j.ejvs.2018.02.001
  3. Ketteler, M., Block, G. A., Evenepoel, P., Fukagawa, M., Herzog, C. A., McCann, L., Moe, S. M., Shroff, R., Tonelli, M. A., Toussaint, N. D., Vervloet, M. G., & Leonard, M. B. (2017). Executive summary of the 2017 KDIGO chronic kidney disease-mineral and bone disorder (CKD-MBD) guideline update: What's changed and why it matters. Kidney International, 92(1), 26-36. https://doi.org/10.1016/j.kint.2017.04.006
  4. Inston, N., Mistry, H., Gilbert, J., Kingsmore, D., Raza, Z., Tozzi, M., Azizzadeh, A., Jones, R., Deane, C., Wilkins, J., Davidson, I., Ross, J., Gibbs, P., Huang, D., & Valenti, D. (2017). Aneurysms in vascular access: State of the art and future developments. The Journal of Vascular Access, 18(6), 464-472. https://doi.org/10.5301/jva.5000828
Dr. W Rivero, MD

W Rivero, MD, FPCP, DPSN

Specialist in Internal Medicine, Nephrology, and Clinical Nutrition. Practicing integrative and evidence-based nephrology across Quezon City, Pampanga, and Bulacan.

· Book an Appointment →

QR code — scan to save Dr. Rivero's contact info

Scan and save